Lactoferrin for the Treatment of COVID‑19

Lactoferrin for the Treatment of COVID‑19

The coronavirus disease 2019 (COVID‑19) outbreak was caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2). The clinical outcomes of elderly individuals and those with underlying... read more

Endothelial Activation and Dysfunction in COVID-19

Endothelial Activation and Dysfunction in COVID-19

On 12 March 2020, the outbreak of coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization. As of 4 August 2020, more than 18 million confirmed infections had been reported globally. Most... read more

Necrotizing Pancreatitis: ED Presentation, Evaluation, and Management

Necrotizing Pancreatitis: ED Presentation, Evaluation, and Management

A 40 year-old patient presents with increasing abdominal pain and a new fever. She initially presented to the Emergency Department five days prior for upper abdominal pain. The initial workup showed stable vital signs, mildly... read more

Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with COVID-19 Infection

Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with COVID-19 Infection

Use of ACEI or ARBs prior to hospitalization was not associated with adverse outcomes in COVID-19 and the therapeutic benefits of continuing ACEI or ARB in hospitalized patients with COVID-19 was not offset by adverse outcomes. Data... read more

Lipid Mediators in Critically Ill Patients: A Step Towards Precision Medicine

Lipid Mediators in Critically Ill Patients: A Step Towards Precision Medicine

In this review, we provide an overview of the role of fatty acid-derived lipid mediators as endogenous regulators of the inflammatory, anti-inflammatory and pro-resolving response and future directions for use of clinical... read more

Genetic Mechanisms of Critical Illness in COVID-19

Genetic Mechanisms of Critical Illness in COVID-19

Host-mediated lung inflammation is present, and drives mortality, in critical illness caused by COVID-19. Host genetic variants associated with critical illness may identify mechanistic targets for therapeutic development. Here... read more

Prior Routine Use of NSAIDs and Important Outcomes in Hospitalised COVID-19 Patients

Prior Routine Use of NSAIDs and Important Outcomes in Hospitalised COVID-19 Patients

Coronavirus disease 2019 (COVID-19) infection causes acute lung injury, resulting from aggressive inflammation initiated by viral replication. There has been much speculation about the potential role of non-steroidal inflammatory... read more

Endothelial Dysfunction Role During COVID-19

Endothelial Dysfunction Role During COVID-19

Emerging data suggest a crucial role of endothelial dysfunction during SARS-CoV-2 infection, as a direct target of the virus and inflammatory cytokines as well as the main actor in orchestrating a pro-inflammatory and pro-coagulant... read more

Stress Hyperglycemia and Mortality in Subjects With Diabetes and Sepsis

Stress Hyperglycemia and Mortality in Subjects With Diabetes and Sepsis

Stress-induced hyperglycemia is a relevant prognostic factor also in the presence of diabetes. Mild-to-moderate stress hyperglycemia is considered a protective reaction to providing fuel for the immune system and brain at... read more

Gastrointestinal Complications in Critically Ill Patients With and Without COVID-19

Gastrointestinal Complications in Critically Ill Patients With and Without COVID-19

This study found a higher rate of gastrointestinal complications, including mesenteric ischemia, in critically ill patients with COVID-19 compared with propensity score–matched patients without COVID-19, suggesting a distinct... read more

Fibrin-derived Peptide as Salvage Treatment in Critically Ill Patients with COVID-19-associated ARDS

Fibrin-derived Peptide as Salvage Treatment in Critically Ill Patients with COVID-19-associated ARDS

After SARS-CoV-2 first occurred in China in December of 2019, it set out to become a global pandemic. Critically ill patients constitute about 2–9% of all infected patients and progress from pneumonia and hypoxemia to multi-organ... read more

Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children

Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children

Acute myocarditis with intense systemic inflammation and atypical Kawasaki disease is an emerging severe pediatric disease following SARS-CoV-2 infection. Early recognition of this disease is needed and referral to an expert... read more

Plasma Exchange in Critically Ill COVID-19 Patients

Plasma Exchange in Critically Ill COVID-19 Patients

The spectrum of coronavirus disease 2019 (COVID-19) ranges from asymptomatic infection to respiratory failure and death of patients. Severely affected patients may develop a cytokine storm-like clinical syndrome with multi-organ... read more

Laboratory Features of Severe vs. Non-severe COVID-19 Patients in Asian Populations

Laboratory Features of Severe vs. Non-severe COVID-19 Patients in Asian Populations

This meta-analysis provides evidence for the differentiation of severe cases of COVID-19 based on laboratory test results at the time of ICU admission. Future well-methodologically designed studies from other populations... read more